Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
C
CAMX
Cambiar Aggressive Value ETF
31.4
8
USD
-1.66%
Sector:
Financial
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-1.66%
Monthly Change
-3.41%
6 month change
-3.41%
Year Change
-3.41%
Previous Close
32.0
1
Open
31.4
4
Low
31.4
4
High
31.4
8
Volume
2
Markets
US ETFs
CAMX
Open full chart
Full chart
Overview
All holdings
Heatmap
Top holdings
Market Value
Shares
Weight %
ELV
ELEVANCE HEALTH, INC.
3.3018 M
9 550.0000
5.1494%
HON
HONEYWELL INTERNATIONAL INCORPORATION
3.2062 M
14.0920 K
5.0003%
UBER
UBER TECHNOLOGIES, INC.
3.0739 M
38.4000 K
4.7940%
MDT
MEDTRONIC PUBLIC LIMITED COMPANY
2.7143 M
26.3630 K
4.2332%
CME
CME GROUP INC.
2.6466 M
9 156.0000
4.1276%
TXN
TEXAS INSTRUMENTS INCORPORATED
2.5866 M
12.0000 K
4.0340%
UNP
UNION PACIFIC CORPORATION
2.5861 M
11.0000 K
4.0332%
NXPI
NXP Semiconductors N.V.
2.5400 M
11.2320 K
3.9613%
BMY
BRISTOL-MYERS SQUIBB COMPANY
2.4645 M
44.7680 K
3.8435%
Nintendo Co., Ltd.
2.4432 M
158.6500 K
3.8103%
Healthcare
23.03 %
Unknown
16.24 %
Industrials
15.97 %
Technology
12.79 %
Consumer Defensive
8.1 %
Financial
5.88 %
News
Camurus reports Q4 revenue miss, lowers 2026 outlook
FDA accepts Camurus’ resubmission for acromegaly treatment Oclaiz
Camurus Q3 2025 slides: Revenue up 18% but stock dips on lowered guidance
Camurus cuts 2025 revenue forecast as Buvidal sales miss estimates
Camurus Q2 2025 slides reveal 52% revenue surge and key regulatory milestones
Earnings call transcript: Camurus AB Q2 2025 earnings beat expectations
Camurus Q2 2025 slides: Record revenue and profit amid product portfolio expansion
Camurus’ POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
Eli Lilly Bets $870 Million on Extended-Release Obesity Drugs
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal ® incretins
Camurus Q1 2025 slides: record profitability despite market challenges
Camurus stock falls on 1Q revenue miss